Úspěšná terapie české pacientky s ROS1 translokací crizotinibem
[Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib]
Jazyk čeština Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
26879065
DOI
10.14735/amko201663
PII: 57428
- MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- krizotinib MeSH
- lidé MeSH
- nádory plic farmakoterapie genetika MeSH
- protoonkogenní proteiny genetika MeSH
- pyrazoly terapeutické užití MeSH
- pyridiny terapeutické užití MeSH
- translokace genetická * MeSH
- tyrosinkinasy genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- inhibitory proteinkinas MeSH
- krizotinib MeSH
- protoonkogenní proteiny MeSH
- pyrazoly MeSH
- pyridiny MeSH
- ROS1 protein, human MeSH Prohlížeč
- tyrosinkinasy MeSH
Targeted therapy of lung cancer has brought significant improvement in prognosis for a lot of patients with EGFR-sensitive mutations and ALK translocations. Other clinical studies have shown ROS1 translocation as another potential target. Our case report brings probably the first successful use of crizotininib in a patient with ROS1 translocation in the Czech Republic. Treatment was well-tolerated and persists continually. During the control PET/ CT scans, partial regression of the disease was observed. ROS1 translocation becomes another promising target for our patients. Therefore, in our opinion, serious discussion about its inclusion among the basic genetic testing in lung adenocarcinomas should occur.
Citace poskytuje Crossref.org
